VIEW ALL RESEARCH-GROUP

Metabolism and cancer
Menendez’s Lab

DESCRIPTION

Unlocking the metabolic secrets of cancer: Our “Metabolism and Cancer” team studies how cellular metabolism drives cancer growth, drug resistance, and metastasis. We use cutting-edge laboratory experiments, computational tools and clinical trials to validate our discoveries in cancer patients.

MAIN RESEARCH LINES

  1. CANCER METABOLISM

    Metabolic inhibitors for cancer therapy

    • Metabolic mechanisms of tumorigenesis & drug resistance
    • Clinical development of anti-cancer metabolic drugs

    Mitochondria, senescence, and cancer

    • Mitochondria-based elimination of tumor-/metastasis-initiating cells
    • Metabolic therapy-induced senescence (MTIS)

    Metabolo-immunotherapy

    • Tumor cell-intrinsic immunometabolism 
    • Metabolic/dietary interventions and immunotherapy 
  2. BIOCOMPOUNDS
    • Natural biocompounds for cancer treatment
  3. COMPUTATIONAL BIOLOGY & CHEMISTRY
    • Mathematical modeling of cancer
    • Computational design of anti-cancer metabolic drugs

Javier A. Menendez

Group leaders

IP

Elisabet Cuyàs

Researchers

Established researcher (Miguel Servet)

Eila Serrano Hervás

Researchers

Postdoctoral researcher (INVESTIGO)

Sara Verdura

Researchers

Predoctoral researcher

Àngela Llop Hernández

Young investigators

Predoctoral researcher

Júlia López

Young investigators

Predoctoral researcher

Begoña Martín Castillo

Researchers

Established researcher (Unit of Clinical Research, ICO-Girona)

Eugeni López Bonet

Researchers

Established researcher (Hospital Trueta)

Metabolic adaptations in severe obesity: Insights from circulating oxylipins before and after weight loss

/in /by

Clin Nutr. 2023 Dec 6;43(1):246-258. doi: 10.1016/j.clnu.2023.12.002. Online ahead of print. ABSTRACT BACKGROUND: The relationship between lipid mediators and severe obesity remains unclear. Our study investigates the impact of severe obesity on plasma concentrations of oxylipins and fatty acids and explores the consequences of weight loss. METHODS: In the clinical trial identifier NCT05554224 study, 116 […]

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

/in /by

Oncotarget. 2023 Jul 1;14:668. doi: 10.18632/oncotarget.28471. NO ABSTRACT PMID:37395727 | PMC:PMC10317036 | DOI:10.18632/oncotarget.28471

Reduced Graphene Oxide Aerogels Cartridges for Solid Phase Extraction of Benzotriazoles

/in /by

Materials (Basel). 2023 Mar 22;16(6):2519. doi: 10.3390/ma16062519. ABSTRACT UV-benzotriazoles have been identified as water micropollutants that cause serious problems for human health and the environment. Their low concentration in water bodies complicates their detection by direct water analysis, slowing the corrective actions to avoid bioaccumulation. In this regard, the use of graphene-based materials with a […]

A robust role for motor cortex

/in /by

Front Neurosci. 2023 Feb 10;17:971980. doi: 10.3389/fnins.2023.971980. eCollection 2023. ABSTRACT The role of motor cortex in non-primate mammals remains unclear. More than a century of stimulation, anatomical and electrophysiological studies has implicated neural activity in this region with all kinds of movement. However, following the removal of motor cortex, rats retain most of their adaptive […]

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells

/in /by

Cancers (Basel). 2022 Dec 16;14(24):6214. doi: 10.3390/cancers14246214. ABSTRACT Epithelial-to-mesenchymal transition (EMT) is key to tumor aggressiveness, therapy resistance, and immune escape in breast cancer. Because metabolic traits might be involved along the EMT continuum, we investigated whether human breast epithelial cells engineered to stably acquire a mesenchymal phenotype in non-tumorigenic and H-RasV12-driven tumorigenic backgrounds possess […]

Ruth Lupu | Mayo Clinic, Rochester, USA

Pilar Blancafort | Harry Perkins Institute of Medical Research, Perth, Australia

Francesca Cutruzzolà | Sapienza University, Rome, Italy

Tomás Alarcón | ICREA-Centre de Recerca Matemàtica (CRM), Reus, Spain

Sílvia Osuna | ICREA-Institut de Química Computacional i Catàlisi (IQCC), Girona, Spain

Josep Sardanyés | Centre de Recerca Matemàtica (CRM), Barcelona, Spain

José Antonio Encinar | Universidad Miguel Hernández, Elche, Spain

Vicente Micol | Universidad Miguel Hernández, Elche, Spain

Antonio Segura-Carretero | Universidad de Granada, Granada, Spain

Jorge Joven | Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain

Carlos Peña Garay | Laboratorio Subterráneo de Canfranc (LSC), Spain

Menendez grup. Research group photo
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

Pujana’s LabPujana's LabGrup-Hematoligia-webSureda’s & Farre’s Lab